This article is part of the supplement: Current trends in leukemia, lymphoma, myeloma and ITP: updates and highlights from ASH 2008
Meeting abstract
Recent progress in the treatment of multiple myeloma: updates and highlights from ASH 2008
-
Correspondence: Sundar Jagannath sjagannath@aptiumoncology.com
Saint Vincent's Comprehensive Cancer Center, New York, NY, USA
Journal of Hematology & Oncology 2009, 2(Suppl 1):A4 doi:10.1186/1756-8722-2-S1-A4
Published: 26 June 2009First paragraph (this article has no abstract)
The treatment of multiple myeloma has rapidly evolved over the past 8 years. During this period we have seen the introduction of two immunomodulatory drugs and a proteasome inhibitor for the treatment of myeloma. Each of these drugs has shown to be effective as single agent as well as in combinations in relapsed and/or refractory myeloma. And the optimum use of these drugs upfront, both for transplant eligible as well as transplant ineligible patients has been the focus of intense clinical investigations as reported by the investigators from US as well as Europe in the last ASH meeting.